Is NXP Semiconductors Undervalued?
NXP Semiconductors (NASDAQ:NXPI) is a large European semiconductor business that…
Buy
60
KVUE Quote, Financials, Valuation and Earnings
Last price:
$21.19
Seasonality move
:
-3.26%
Day range:
$21.00 - $21.29
52-week range:
$19.75 - $25.17
Dividend yield:
3.88%
P/E ratio:
28.65x
P/S ratio:
2.70x
P/B ratio:
3.79x
Volume:
16.1M
Avg. volume:
19.9M
1-year change:
-1.72%
Market cap:
$40.7B
Revenue:
$15.5B
EPS (TTM):
$0.74
Analysts' Opinion
-
Consensus RatingKenvue has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.80, Kenvue has an estimated upside of 7.55% from its current price of $21.20.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $21.20.
Fair Value
-
According to the consensus of 15 analysts, Kenvue has 7.55% upside to fair value with a price target of $22.80 per share.
KVUE vs. S&P 500
-
Over the past 5 trading days, Kenvue has underperformed the S&P 500 by -0.65% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kenvue does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kenvue revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Kenvue reported revenues of $3.8B.
Earnings Growth
-
Kenvue has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Kenvue reported earnings per share of $0.22.
Enterprise value:
48.4B
EV / Invested capital:
2.48x
Price / LTM sales:
2.70x
EV / EBIT:
18.23x
EV / Revenue:
3.19x
PEG ratio (5yr expected):
0.26x
EV / Free cash flow:
29.72x
Price / Operating cash flow:
25.10x
Enterprise value / EBITDA:
14.83x
Gross Profit (TTM):
$8.8B
Return On Assets:
5.36%
Net Income Margin (TTM):
9.37%
Return On Equity:
13.83%
Return On Invested Capital:
7.46%
Operating Margin:
19.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | $15.4B | $15.5B | $15.1B | $4B | $3.8B | |
| Gross Profit | $8.5B | $8.9B | $8.8B | $2.4B | $2.3B | |
| Operating Income | $3B | $2.9B | $2.7B | $716M | $752M | |
| EBITDA | $3.6B | $3.5B | $3.3B | $857M | $894M | |
| Diluted EPS | $0.27 | $0.35 | $0.74 | $0.03 | $0.22 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $6.2B | $5.9B | $5.9B | |
| Total Assets | -- | -- | $27.5B | $26.4B | $27.1B | |
| Current Liabilities | -- | -- | $5.3B | $5.9B | $6B | |
| Total Liabilities | -- | -- | $16.5B | $16.3B | $16.4B | |
| Total Equity | -- | -- | $11B | $10.2B | $10.7B | |
| Total Debt | -- | -- | $8.6B | $8.6B | $8.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.9B | $2.4B | $2.1B | $440M | $621M | |
| Cash From Investing | -$393M | -$607M | -$445M | -$85M | -$90M | |
| Cash From Financing | -$2.1B | -$1.9B | -$1.6B | -$490M | -$548M | |
| Free Cash Flow | $2.5B | $1.8B | $1.6B | $350M | $533M | |
KVUE
Sector
Market Cap
$40.7B
$219M
Price % of 52-Week High
84.23%
74.14%
Dividend Yield
3.88%
0%
Shareholder Yield
4.57%
2.74%
1-Year Price Total Return
-1.72%
-9.69%
Beta (5-Year)
--
0.378
Dividend yield:
3.88%
Annualized payout:
$0.81
Payout ratio:
-110.79%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$21.45
200-day SMA
Sell
Level
$22.42
Bollinger Bands (100)
Sell
Level
21.35 - 23.49
Chaikin Money Flow
Sell
Level
-9.5M
20-day SMA
Sell
Level
$21.87
Relative Strength Index (RSI14)
Sell
Level
44.24
ADX Line
Sell
Level
25.9
Williams %R
Neutral
Level
-76.7802
50-day SMA
Sell
Level
$21.56
MACD (12, 26)
Buy
Level
5.20
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-89.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4691)
Buy
CA Score
(Annual)
Level (-0.2932)
Buy
Beneish M-Score
(Annual)
Level (-2.4453)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (0.1673)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.
Stock Forecast FAQ
In the current month, KVUE has received 3 Buy ratings 12 Hold ratings, and 0 Sell ratings. The KVUE average analyst price target in the past 3 months is $22.80.
-
Where Will Kenvue Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kenvue share price will rise to $22.80 per share over the next 12 months.
-
What Do Analysts Say About Kenvue?
Analysts are divided on their view about Kenvue share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kenvue is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Kenvue's Price Target?
The price target for Kenvue over the next 1-year time period is forecast to be $22.80 according to 15 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is KVUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kenvue is a Hold. 12 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of KVUE?
You can purchase shares of Kenvue via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kenvue shares.
-
What Is The Kenvue Share Price Today?
Kenvue was last trading at $21.19 per share. This represents the most recent stock quote for Kenvue. Yesterday, Kenvue closed at $21.20 per share.
-
How To Buy Kenvue Stock Online?
In order to purchase Kenvue stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Intel Stock Undervalued?
In Q2 2025, Intel reported $12.9 billion in revenue, which…
Is Sinclair Stock a Short?
If you strip away the buzzwords, Sinclair’s business is still…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Sell
50
Is MSFT Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Alerts
Sell
48
NEGG alert for Aug 16
Newegg Commerce [NEGG] is down 21.62% over the past day.
Sell
35
SEDG alert for Aug 16
Solaredge Technologies [SEDG] is up 17.26% over the past day.
Buy
62
NUTX alert for Aug 16
Nutex Health [NUTX] is down 16.44% over the past day.
